One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Epidemiology and Natural History of Perianal Crohn’s Disease: A Systematic Review and Meta-Analysis of Population-Based Cohorts
Lester Tsai, MD, Jeffrey D McCurdy, MD, PhD, Christopher Ma, MD, MPH, Vipul Jairath, MD, PhD, Siddharth Singh, MD, MS
doi : 10.1093/ibd/izab287
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Pages 1477–1484
Molecular Network Analyses Implicate Death-Associated Protein Kinase 3 (DAPK3) as a Key Factor in Colitis-Associated Dysplasia Progression
Huey-Miin Chen, PhD, Justin A MacDonald, PhD
doi : 10.1093/ibd/izac098
Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID
Kimberly N Weaver, MD, Xian Zhang, PhD, Xiangfeng Dai, PhD, Runa Watkins, MD, Jeremy Adler, MD, MSc, Marla C Dubinsky, MD, Arthur Kastl, MD, Athos Bousvaros, MD, MPH, Jennifer A Strople, MD, Raymond K Cross, MD, MS, Peter D R Higgins, MD, PhD, Ryan C Ungaro, MD, MS, Meenakshi Bewtra, MD, PhD, Emanuelle Bellaguarda, MD, Francis A Farraye, MD, MS, Margie E Boccieri, MA, Ann Firestine, MS, Michael D Kappelman, MD, MPH, Millie D Long, MD, MPH
doi : 10.1093/ibd/izab302
Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study
Karin Cerna, MD, Dana Duricova, MD, PhD, Martin Lukas, MD, Nadezda Machkova, MD, Veronika Hruba, MD, Katarina Mitrova, MD, Kristyna Kubickova, MD, Marta Kostrejova, MD, PhD, Vladimir Teplan, MD, PhD, Martin Vasatko, MD, Kristyna Kastylova, MD, Milan Lukas, MD, PhD
doi : 10.1093/ibd/izab301
Mesalazine in Inflammatory Bowel Disease and COVID-19: Hospitalization and Adverse In-Hospital Outcomes Based on Nationwide Data
Simon Kjeldsen, Jan Nielsen, PhD, Bente Mertz Nørgård, Phd, DMSc, Jens Kjeldsen, PhD
doi : 10.1093/ibd/izab299
Association Between Inflammatory Bowel Disease and Dementia: A Longitudinal Cohort Study
Yuhao Sun, MBBS, Jiawei Geng, PhD, Xuejie Chen, MM, Hui Chen, BS, Xiaoyan Wang, PhD, MD, Jie Chen, PhD, Xue Li, PhD, Therese Hesketh, PhD
doi : 10.1093/ibd/izab300
The Magnitude of Crohn’s Disease Direct Costs in Health Care Systems (from Different Perspectives): A Systematic Review
Mafalda Santiago, BSc, Cláudia Camila Dias, PhD, Catarina Alves, MSc, Paula Ministro, MD, Raquel Gonçalves, MD, Diana Carvalho, MD, Francisco Portela, MD, LuÃs Correia, MD, Paula Lago, MD, Fernando Magro, MD, PhD
doi : 10.1093/ibd/izab334
Quantification of Mucosal Activity from Colonoscopy Reports via the Simplified Endoscopic Mucosal Assessment for Crohn’s Disease
Jeremy Adler, MD, MSc, Sally J Eder, BA, Acham Gebremariam, MS, Christopher J Moran, MD, Lee M Bass, MD, Jonathan Moses, MD, Jeffery D Lewis, MD, Andrew A M Singer, MD, Tina L Morhardt, MD, MS, Joseph A Picoraro, MD, Vanessa Cardenas, MD, George M Zacur, MD, MS, Richard B Colletti, MD
doi : 10.1093/ibd/izab315
Causal Association Between Atopic Dermatitis and Inflammatory Bowel Disease: A 2-Sample Bidirectional Mendelian Randomization Study
Christa Meisinger, MD, MPH, Dennis Freuer, MSc
doi : 10.1093/ibd/izab329
A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab
Dino Tarabar, MD, PhD, Katia El Jurdi, MD, Cindy Traboulsi, MD, Olivia Yvellez, BA, Zoran Milenkovic, MD, Stanko Petrovic, MD, Bojana Subotic, MD, Ann Gils, PhD, Tanja Brocic, MD, Irina Brcerevic, MD, Olgica Latinovic, MD, Tanja Jocic, MD, David T Rubin, MD
doi : 10.1093/ibd/izab328
Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab
Parambir S Dulai, MD, Emily C L Wong, BS, Walter Reinisch, MD, Jean-Frederic Colombel, MD, John K Marshall, MD, MSc, Neeraj Narula, MD
doi : 10.1093/ibd/izab310
Health Confidence Is Associated With Disease Outcomes and Health Care Utilization in Inflammatory Bowel Disease: A Nationwide Cross-sectional Study
Chung Sang Tse, MD, Corey A Siegel, MD, MS, S Alandra Weaver, Brant J Oliver, PhD, MS, MPH, FNP-BC, PMHNP-BC, Catherine Bresee, MS, Welmoed K van Deen, MD, PhD, Gil Y Melmed, MD, MS
doi : 10.1093/ibd/izab313
A Systematic Review of Artificial Intelligence and Machine Learning Applications to Inflammatory Bowel Disease, with Practical Guidelines for Interpretation
Imogen S Stafford, MSci, Mark M Gosink, PhD, Enrico Mossotto, PhD, Sarah Ennis, PhD, Manfred Hauben, MD, MPH
doi : 10.1093/ibd/izac115
Microscopic Colitis Is Associated With a Reduced Risk of Colorectal Adenoma and Cancer: A Meta-Analysis
Yi-hui Liu, MSc, Zhen Wu, MSc, Ji-yuan Ding, MSc, Yu-dan Shi, MSc
doi : 10.1093/ibd/izab333
Use and Misuse of Parenteral Nutrition in Patients with Inflammatory Bowel Disease
Alfred D Nelson, MD, Jaclyn R Elkins, MS, RDN, CNSC, Luca Stocchi, MD, Francis A Farraye, MD, MSc, Jana G Hashash, MD, MSc
doi : 10.1093/ibd/izac085
Normal Sperm DNA Integrity in Patients With Inflammatory Bowel Disease on Ustekinumab Maintenance Therapy
Anne Grosen, MD, PhD, Emanuelle Bellaguarda, MD, Ingela Liljeqvist-Soltic, MSc, PhD, Mette Mejlby Hansen, MSc, Anne-Bine Skytte, MD, PhD, Mette Julsgaard, MD, PhD, Stephen B Hanauer, MD, Professor, Jens Kelsen, MD, PhD
doi : 10.1093/ibd/izac028
Balsalazide Exposure During the Development of Fertilizing Sperm May Be Associated With Offspring Birth Defects
Maarten J Wensink, MD, PhD, Sarah E Streett, MD, AGAF, Per Damkier, MD, PhD, Rune Lindahl-Jacobsen, PhD, Jens Kjeldsen, MD, PhD, Michael L Eisenberg, MD
doi : 10.1093/ibd/izac038
Vancomycin Is Effective in the Treatment of Chronic Inflammatory Conditions of the Pouch
Gabriel Lupu, MD, Kimberly N Weaver, MD, Hans H Herfarth, MD, PhD, Edward L Barnes, MD, MPH
doi : 10.1093/ibd/izac043
Natural History of New-onset Inflammatory Bowel Disease Among Patients With Multiple Sclerosis
Shiv Gandhi, MD, Sara Zelman, MD, Ricardo Eduardo De Armas, MD, Christopher Hemond, MD, Alexander N Levy, MD, Siddharth Singh, MS, MD, Joshua Korzenik, MD, Sushrut Jangi, MD
doi : 10.1093/ibd/izac053
Association Between the Clinical, Biochemical, and Endoscopic Activity of Inflammatory Bowel Diseases and Severity and Long-term Outcomes of Coronavirus Disease 2019—A Population-based Study
Mohamed Attauabi, MD, Jens Frederik Dahlerup, MD, DMsc, Anja Poulsen, MD, Malte Rosager Hansen, MD, Marianne Kajbæk Vester-Andersen, MD, PhD, August Pilegaard Prahm, MD, Natalia Pedersen, MD, PhD, Lone Larsen, MD, PhD, Tine Jess, MD, DMSc, Anders Neumann, MD, PhD, Kent V Haderslev, MD, DMSc, Akbar Molazahi, MD, Anders Berg Lødrup, MD, PhD, Henning Glerup, MD, DMSc, Asser Mathiassen Oppfeldt, MD, PhD, Michael Dam Jensen, MD, PhD, Klaus Theede, MD, PhD, Marianne Kiszka-Kanowitz, MD, Jakob Benedict Seidelin, MD, PhD, DMSc, Johan Burisch, MD, PhD
doi : 10.1093/ibd/izac052
De Novo Pediatric Ulcerative Colitis Triggered by SARS-CoV-2 Infection: a Tale of 2 Sisters
Nicholas A Preziosi, MD, Areeba H Rizvi, MD, John D Feerick, MD, Chetan Mandelia, MD
doi : 10.1093/ibd/izac142
Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: A Survey From China
Wen-ning Tian, MD, PhD, Yu-hong Huang, MD, PhD, Cong Dai, MD, PhD
doi : 10.1093/ibd/izac118
Should a Psychologist Be a Mandatory Component of Inflammatory Bowel Disease Consults? Yes
Neel Sharma, BSc, MBChB, MSc, MRCP (UK), PhD
doi : 10.1093/ibd/izac123
Should a Psychologist Be a Mandatory Component of IBD Consults? Yes—Authors' Reply
Sebastian Bruno Ulrich Jordi, MD, Stefan Begré, MD, Benjamin Misselwitz, MD
doi : 10.1093/ibd/izac125
Patient With Ulcerative Colitis and Failure of Ustekinumab Responds to Risankizumab: Similar Is Not Identical
Yonatan Ziv, MD, Arun Swaminath, MD, Keith Sultan, MD
doi : 10.1093/ibd/izac072
Correspondence on “Immunogenicity of COVID-19 Vaccine Doses in Patients With Inflammatory Bowel Disease�
Pathum Sookaromdee, PhD, Viroj Wiwanitkit, MD
doi : 10.1093/ibd/izac108
Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial
Wenhui Zhang, PhD, Astrid Scalori, MD, Franklin Fuh, BS, Jacqueline McBride, PhD, Gaohong She, MS, Jaroslaw Kierkus, MD, PhD, Bartosz Korczowski, MD, PhD, Regan Li, MSc, Mariam Abouhossein, PharmD, RPh, Alysha Kadva, PhD, MA, K T Park, MD, Meina Tao Tang, PhD
doi : 10.1093/ibd/izac066
Correction to: Association Between Inflammatory Bowel Disease and Dementia: A Longitudinal Cohort Study
doi : 10.1093/ibd/izac155
Correction to: Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
doi : 10.1093/ibd/izac163
